Biophytis

A pioneering biotechnology company focused on developing transformative therapies that impact longevity.

[Biophytis @biophytis]

🎥 On the path to a world first, explained by those who made it happen

Stanislas Veillet, CEO of @Biophytis, and Mr. Ding, Chairman of Ronghui Renhe Life Technology, share the vision behind our Hong Kong joint venture.

👉 Toward the world’s first Phase 3 trial in sarcopenia

[Biophytis @biophytis]

We’re unveiling our new website: https://t.co/Yrgkb3ucDz ✨

Spotlight on our Three Strategic Pillars:
🧪 Longevity Research Platform (AI‑accelerated)
💪 BIO101 in Sarcopenia
🏃 BIO101 in Obesity

🎥 Watch the video & explore the site.

#Biotech #Longevity #HealthyAging

[Biophytis @biophytis]

« Dans la #sarcopénie, nous visons un lancement en 2031 en Europe et en Asie pour un potentiel de 1,2 Md€ » — S. Veillet, PDG de #Biophytis

Merci à @Boursier_com et Christophe Voisin pour cet entretien autour de #BIO101 et de la longévité.

👉 https://t.co/Pgm5zczAHC

#Biotech

[Biophytis @biophytis]

🎙️Biophytis vous donne rendez-vous sur Zoom le 20 octobre à 18 h (CET) pour une session d'échange avec ses dirigeants sur ses partenariats dans la sarcopénie et ses perspectives 2026.

🔗 Inscrivez-vous ici : https://t.co/oCIxUGwzYz

[Biophytis @biophytis]

🌍 Big news from #Biophytis!
We’re joining forces with Ronghui Renhe & Asian investors to launch the world’s 1st Phase 3 trial in sarcopenia with #BIO101 — a US$20M JV in Hong Kong, starting early 2026 with 932 patients across Europe & Asia.
👉 https://t.co/bkh8KqNrJ0
#Longevity

[Biophytis @biophytis]

🎥 @Biophytis Insights

"An extraordinary proof of interest" – Stanislas Veillet, CEO

With almost 50% of co-financing from @EMBRAPII and two top strategic partners, we’re preparing for our Phase 2 OBA clinical trial in obesity in Brazil !

📺 Watch now

[Biophytis @biophytis]

@Biophytis unveils strategy for the 1st-ever Phase 3 trial in sarcopenia 💪

📄 Full press release : https://t.co/hrNoyMBkpC

[Biophytis @biophytis]

Biophytis will attend the @BIOConvention in Boston (June 16–19) to share updates on BIO101 in #obesity and explore new strategic partnerships 🤝 !

More information here👇
https://t.co/Lcu7JNATBw

[Biophytis @biophytis]

@biophytis - Live Healthier Longer était à l'#ECO2025, le congrès européen de l'obésité 💡

🧬 Notre chef de projet Recherche Clinique, le Dr Serge Camelo y a présenté les dernières données du programme OBA sur BIO101 !

La présentation complète ici👇
https://t.co/IlbSEjOShY

[Biophytis @biophytis]

Biophytis will participate in #ECO2025 from May 11–14 in Malaga!

📅 May 12, 5:15 PM: Dr. Camelo presents "OBA : a phase 2 trial evaluating BIO101 (20E) to combat muscle loss induced by semaglutide in obesity treatment."

#Obesity #Pharmacotherapy #ClinicalTrials

[Biophytis @biophytis]

@Biophytis pioneers mobility restoration in obesity! 🧬
Promising BIO101 + GLP-1 results presented at #ICFSR25, Phase 2 OBA trial ahead 🔜

Details ⬇️
https://t.co/BAACrX1kEB

#ObesityResearch

[Biophytis @biophytis]

🔬 @Biophytis is excited to announce a world premiere in sarcopenia with the publication of the Phase 2 clinical trial SARA-INT ! This paves the way for the upcoming launch of Phase 3 study 💪

📖 Read the full publication here : https://t.co/bPcwvJcyCR

[Biophytis @biophytis]

@biophytis' CEO Stanislas Veillet went live at the Life Sciences Virtual Investor Conference, in partnership with @OTCMarkets to present our company's ambition in the field of obesity 📈

Watch the conference here: https://t.co/jVp0OmiABK

[Biophytis @biophytis]

« Make a life-changing impact for people suffering from obesity »

Present at @SachsAssociates first Biopharma Obesity Innovation Forum, our CEO Stanislas Veillet shared Biophytis’ vision for 2025 📈

🎬 Watch his full intervention here👇
https://t.co/gJlgRbqqEB

[Biophytis @biophytis]

Biophytis🤝AskHelpU

Biophytis et AskHelpU, la plus grande association chinoise dédiée à la SLA, unissent leurs forces pour évaluer BIO101 dans la lutte contre cette maladie touchant 200 000 patients en Chine.

Plus d'informations sur ce partenariat ⬇️
https://t.co/524GzhSLIU

[Biophytis @biophytis]

🚨 Négociations exclusives pour licencier BIO101 en Chine avec un laboratoire pharmaceutique chinois de premier plan ! 🇨🇳

Stanislas Veillet, PDG 🎙️ : « Ce partenariat peut nous permettre de rentrer dans une nouvelle ère pour la société en finalisant le développement de BIO101 ».

[Biophytis @biophytis]

Our CEO, Stanislas Veillet, presented Biophytis' strategic vision and advances in the treatment of obesity on January 11 ahead of the J.P. Morgan Healthcare conference. 🚀

The presentations will 🔜 be uploaded on our website.

👉 Stay tuned as we participate in the BIO@JPM Week.

[Biophytis @biophytis]

Happy new year !

Biophytis is starting 2025 by presenting at the 1st Annual BioPharma Obesity Innovation Forum prior to the J.P. Morgan 43rd Annual Healthcare Conference on Saturday, January 11 at 1.50 pm PST.

For more information👇
https://t.co/c6Bzotx58e

[Biophytis @biophytis]

📢 Replay now available !

Relive Biophytis’ Investor Call at SCWD 2024 🎥 and download the slides 📄: https://t.co/AyAsP3iKhR

💡 Focus: GLP-1 RA weight loss therapy-induced muscle loss.

#Biophytis #SCWD2024 #Health #Innovation

[Biophytis @biophytis]

Biophytis will be at the 17th edition of the @SCWDnews Congress! 🏛️
Alongside the event, we are hosting an Investor Call: “GLP-1 RA weight loss therapy-induced muscle loss: A medical need to explore?” 📈
Join us on Dec 6 at 12:45 PM (ET) / 18H45 PM (CET)👇
https://t.co/lwDWprRyY0